- Home
- HOFT vs JSPR Comparison
HOFT vs JSPR Comparison
Compare HOFT & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOFT
- JSPR
- Stock Information
- Founded
- HOFT 1924
- JSPR 2018
- Country
- HOFT United States
- JSPR United States
- Employees
- HOFT N/A
- JSPR N/A
- Industry
- HOFT Home Furnishings
- JSPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HOFT Consumer Discretionary
- JSPR Health Care
- Exchange
- HOFT Nasdaq
- JSPR Nasdaq
- Market Cap
- HOFT 98.1M
- JSPR 85.8M
- IPO Year
- HOFT 1999
- JSPR N/A
- Fundamental
- Price
- HOFT $8.69
- JSPR $3.97
- Analyst Decision
- HOFT
- JSPR Strong Buy
- Analyst Count
- HOFT 0
- JSPR 10
- Target Price
- HOFT N/A
- JSPR $62.50
- AVG Volume (30 Days)
- HOFT 107.8K
- JSPR 183.3K
- Earning Date
- HOFT 04-17-2025
- JSPR 05-13-2025
- Dividend Yield
- HOFT 10.59%
- JSPR N/A
- EPS Growth
- HOFT N/A
- JSPR N/A
- EPS
- HOFT N/A
- JSPR N/A
- Revenue
- HOFT $397,465,000.00
- JSPR N/A
- Revenue This Year
- HOFT $12.50
- JSPR N/A
- Revenue Next Year
- HOFT $7.72
- JSPR N/A
- P/E Ratio
- HOFT N/A
- JSPR N/A
- Revenue Growth
- HOFT N/A
- JSPR N/A
- 52 Week Low
- HOFT $7.34
- JSPR $3.13
- 52 Week High
- HOFT $19.79
- JSPR $26.84
- Technical
- Relative Strength Index (RSI)
- HOFT 38.06
- JSPR 38.01
- Support Level
- HOFT $7.77
- JSPR $3.87
- Resistance Level
- HOFT $8.61
- JSPR $4.40
- Average True Range (ATR)
- HOFT 0.79
- JSPR 0.34
- MACD
- HOFT -0.04
- JSPR 0.09
- Stochastic Oscillator
- HOFT 42.45
- JSPR 66.14
About HOFT Hooker Furnishings Corporation
Hooker Furnishings Corp designs, imports, manufactures and market residential household furniture, hospitality and contract furniture, lighting, accessories, and home décor for sale to wholesale and retail merchandisers located principally in North America.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.